- Home
- CTOS vs NTLA Comparison
CTOS vs NTLA Comparison
Compare CTOS & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTOS
- NTLA
- Stock Information
- Founded
- CTOS 1988
- NTLA 2014
- Country
- CTOS United States
- NTLA United States
- Employees
- CTOS N/A
- NTLA N/A
- Industry
- CTOS Diversified Commercial Services
- NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- CTOS Consumer Discretionary
- NTLA Health Care
- Exchange
- CTOS Nasdaq
- NTLA Nasdaq
- Market Cap
- CTOS 1.1B
- NTLA 1.0B
- IPO Year
- CTOS N/A
- NTLA 2016
- Fundamental
- Price
- CTOS $4.22
- NTLA $7.11
- Analyst Decision
- CTOS Buy
- NTLA Buy
- Analyst Count
- CTOS 4
- NTLA 18
- Target Price
- CTOS $5.88
- NTLA $39.44
- AVG Volume (30 Days)
- CTOS 750.1K
- NTLA 3.3M
- Earning Date
- CTOS 03-04-2025
- NTLA 05-08-2025
- Dividend Yield
- CTOS N/A
- NTLA N/A
- EPS Growth
- CTOS N/A
- NTLA N/A
- EPS
- CTOS N/A
- NTLA N/A
- Revenue
- CTOS $1,802,280,000.00
- NTLA $57,877,000.00
- Revenue This Year
- CTOS $5.31
- NTLA N/A
- Revenue Next Year
- CTOS $8.22
- NTLA N/A
- P/E Ratio
- CTOS N/A
- NTLA N/A
- Revenue Growth
- CTOS N/A
- NTLA 59.55
- 52 Week Low
- CTOS $3.03
- NTLA $6.98
- 52 Week High
- CTOS $6.27
- NTLA $28.18
- Technical
- Relative Strength Index (RSI)
- CTOS 37.88
- NTLA 30.42
- Support Level
- CTOS $4.65
- NTLA $8.50
- Resistance Level
- CTOS $5.26
- NTLA $9.38
- Average True Range (ATR)
- CTOS 0.22
- NTLA 0.62
- MACD
- CTOS -0.04
- NTLA -0.15
- Stochastic Oscillator
- CTOS 1.89
- NTLA 4.21
About CTOS Custom Truck One Source Inc.
Custom Truck One Source Inc is a one-stop-shop provider of specialty equipment in the electric utility transmission and distribution, forestry, telecom, waste management, rail, and infrastructure end-markets in North America. The company's segment includes Equipment Rental Solutions (ERS), Truck and Equipment Sales (TES), and Aftermarket Parts and Services (APS). It generates maximum revenue from the TES segment. Geographically, it derives a majority revenue from the United States.
About NTLA Intellia Therapeutics Inc.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.